Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.34 |
| ▸ | VHL | P40337 | 1/20 | 0.34 |
| ▸ | ELOC | Q15369 | 1/20 | 0.34 |
| ▸ | ELOB | Q15370 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5173319 | 1.00 | USP30 (0.38) | USP30HCRTR2HDAC6UCHL1GPR119 | |
| SCHEMBL5130041 | 0.90 | UCHL1 (0.43) | USP30HCRTR2HDAC6UCHL1GPR119 | |
| SCHEMBL5115026 | 0.90 | UCHL1 (0.43) | USP30HCRTR2HDAC6UCHL1GPR119 | |
| SCHEMBL5123655 | 0.88 | HDAC6 (0.38) | USP30HCRTR2HDAC6UCHL1GPR119 | |
| SCHEMBL5119061 | 0.86 | CYP1A2 (0.41) | USP30HCRTR2HDAC6GPR119SCD5 | |
| SCHEMBL5122491 | 0.86 | CYP1A2 (0.41) | USP30HCRTR2HDAC6GPR119SCD5 | |
| SCHEMBL5130360 | 0.86 | CYP1A2 (0.41) | USP30HCRTR2HDAC6GPR119SCD5 | |
| SCHEMBL15866157 | 0.84 | RIPK1 (0.40) | USP30UCHL1GPR119 | |
| SCHEMBL4908872 | 0.81 | USP30 (0.44) | USP30HCRTR2GPR119SCD5NR1H2 | |
| SCHEMBL4918972 | 0.81 | USP30 (0.44) | USP30HCRTR2GPR119SCD5NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161330-A1 | Pyrimidines as Igf-I Inhibitors | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | PIGS, GPR52, GPR174 | USP30 4388/4885HCRTR2 386/4885HDAC6 1952/4885 |
| US-20080161330-A1 | Pyrimidines as Igf-I Inhibitors | IGF1R, IGFBP1, IGFBP2 | USP30 4042/4885HCRTR2 3051/4885HDAC6 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.